Partner With Us
Research & Clinical Partnerships
Work with us to evaluate existing evidence and, where gaps remain, conduct research to inform clinical decision-making.
Philanthropic Partnerships
Support the identification and evaluation work required to move affordable cancer treatments toward clinical consideration.
Reboot Rx collaborates with clinicians, researchers, health systems, pro bono partners, and philanthropic funders to help move evidence-based, affordable cancer treatments toward clinical evaluation and use.
Our work bridges a structural gap that leaves many evidence-supported treatments without a clear path forward once patents expire. Collaboration and philanthropy together help create pathways the market does not provide.
Pro Bono & Strategic Support
Reboot Rx works with pro bono partners who contribute specialized expertise critical to advancing evidence-based pathways for repurposed generic drugs. These collaborations strengthen our ability to address complex clinical, regulatory, and system-level questions that are often barriers to progress once drugs go off-patent.
Pro bono contributions allow Reboot Rx to extend the reach of philanthropic investments.
Current pro bono partners include:
Gerson Lehrman Group
Access to oncology experts
Costello Medical
Budget impact modeling
Ready to Explore Partnership?
We welcome conversations with research institutions, health system leaders, and philanthropic funders.